These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 33751503)

  • 21. Drug treatment of obsessive-compulsive disorder.
    Kellner M
    Dialogues Clin Neurosci; 2010; 12(2):187-97. PubMed ID: 20623923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.
    Fineberg NA; Reghunandanan S; Brown A; Pampaloni I
    Aust N Z J Psychiatry; 2013 Feb; 47(2):121-41. PubMed ID: 23125399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
    Brakoulias V; Stockings E
    Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obsessive-compulsive disorder.
    Bokor G; Anderson PD
    J Pharm Pract; 2014 Apr; 27(2):116-30. PubMed ID: 24576790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers.
    Van Ameringen M; Simpson W; Patterson B; Dell'Osso B; Fineberg N; Hollander E; Hranov L; Hranov G; Lochner C; Karamustafalioglu O; Marazziti D; Menchon JM; Nicolini H; Pallanti S; Stein DJ; Zohar J
    J Psychopharmacol; 2014 Jun; 28(6):596-602. PubMed ID: 24429223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors.
    Kim CH; Cheon KA; Koo MS; Ryu YH; Lee JD; Chang JW; Lee HS
    Neuropsychobiology; 2007; 55(3-4):156-62. PubMed ID: 17657168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
    Wolmarans de W; Brand L; Stein DJ; Harvey BH
    Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.
    Denys D; van Megen H; Westenberg H
    J Clin Psychiatry; 2002 Aug; 63(8):700-3. PubMed ID: 12197450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice.
    Grados MA; Riddle MA
    J Clin Child Psychol; 2001 Mar; 30(1):67-79. PubMed ID: 11294079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
    Stein DJ; Bouwer C; Hawkridge S; Emsley RA
    J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological management of treatment-resistant obsessive-compulsive disorder.
    Abudy A; Juven-Wetzler A; Zohar J
    CNS Drugs; 2011 Jul; 25(7):585-96. PubMed ID: 21699270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotic treatment in obsessive-compulsive disorder: a literature review.
    Keuneman RJ; Pokos V; Weerasundera R; Castle DJ
    Aust N Z J Psychiatry; 2005 May; 39(5):336-43. PubMed ID: 15860020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder.
    Pallanti S; Hollander E; Goodman WK
    J Clin Psychiatry; 2004; 65 Suppl 14():6-10. PubMed ID: 15554782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based pharmacotherapy of obsessive-compulsive disorder.
    Fineberg NA; Brown A; Reghunandanan S; Pampaloni I
    Int J Neuropsychopharmacol; 2012 Sep; 15(8):1173-91. PubMed ID: 22226028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.